

Eric Hachulla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1164618/publications.pdf>

Version: 2024-02-01

467
papers

44,170
citations

1536

106
h-index

3034

188
g-index

508
all docs

508
docs citations

508
times ranked

28579
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology of Sjögren Syndrome in Africa. Journal of Clinical Rheumatology, 2022, 28, e240-e244.	0.9	3
2	Epidemiology of Idiopathic Inflammatory Myopathies in Africa. Journal of Clinical Rheumatology, 2022, 28, e552-e562.	0.9	8
3	Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France. Journal of Scleroderma and Related Disorders, 2022, 7, 49-56.	1.7	5
4	Localized versus systemic granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry. Rheumatology, 2022, 61, 2464-2471.	1.9	8
5	An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: A study of a national retrospective cohort of 1375 patients over 10 years. Journal of Allergy and Clinical Immunology, 2022, 149, 2116-2125.	2.9	7
6	The consequences of COVID-19 pandemic on patients with monoclonal gammopathy-associated systemic capillary leak syndrome (Clarkson disease). Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 626-629.	3.8	6
7	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Annals of the Rheumatic Diseases, 2022, 81, 695-709.	0.9	130
8	Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. Rheumatology, 2022, 61, 4384-4396.	1.9	10
9	Interstitial pneumonia with autoimmune features: Evaluation of connective tissue disease incidence during follow-up. European Journal of Internal Medicine, 2022, 97, 62-68.	2.2	10
10	Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. Rheumatology, 2022, 61, 4035-4046.	1.9	6
11	Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry. RMD Open, 2022, 8, e002160.	3.8	9
12	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. Rheumatology, 2022, 61, 4786-4796.	1.9	20
13	Challenging the traditional approach for interpreting genetic variants: Lessons from Fabry disease. Clinical Genetics, 2022, 101, 390-402.	2.0	26
14	Health Outcomes of 215 Mothers of Children With Autoimmune Congenital Heart Block: Analysis of the French Neonatal Lupus Syndrome Registry. Journal of Rheumatology, 2022, 49, 1124-1130.	2.0	3
15	Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 1420-1427.	0.9	24
16	Protein-losing Enteropathy as a Complication and/or Differential Diagnosis of Common Variable Immunodeficiency. Journal of Clinical Immunology, 2022, 42, 1461-1472.	3.8	2
17	Dyslipidemia is insufficiently treated in antiphospholipid syndrome patients. Lupus, 2022, 31, 1379-1384.	1.6	6
18	Simple gene signature to assess murine fibroblast polarization. Scientific Reports, 2022, 12, .	3.3	6

#	ARTICLE	IF	CITATIONS
19	Extended myositis-specific and -associated antibodies profile in systemic sclerosis: A cross-sectional study. <i>Joint Bone Spine</i> , 2021, 88, 105048.	1.6	12
20	Serious Infectious Events and Immunoglobulin Replacement Therapy in Patients With Autoimmune Disease Receiving Rituximab: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 727-737.	5.8	25
21	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 219-227.	0.9	160
22	Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS. <i>Rheumatology</i> , 2021, 60, 675-681.	1.9	21
23	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. <i>Rheumatology</i> , 2021, 60, 5028-5041.	1.9	34
24	Systemic Pulmonary Events Associated with Myelodysplastic Syndromes: A Retrospective Multicentre Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1162.	2.4	3
25	Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic). <i>Arthritis Research and Therapy</i> , 2021, 23, 70.	3.5	12
26	¹⁸ F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. <i>Arthritis Research and Therapy</i> , 2021, 23, 76.	3.5	20
27	Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 339-346.	3.4	22
28	Characteristics and risk factors for poor outcome in patients with systemic vasculitis involving the gastrointestinal tract. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 436-441.	3.4	10
29	Correspondence in reference to the previously published Epub manuscript: immune thrombocytopenic purpura after SARS-CoV-2 vaccine. <i>British Journal of Haematology</i> , 2021, 194, e93-e95.	2.5	3
30	COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e419-e426.	3.9	211
31	Étude transversale des profils anticorps spécifiques et associés aux myosites dans la sclérodermie systémique. <i>Revue Du Rhumatisme (Edition Française)</i> , 2021, 88, 284-290.	0.0	0
32	French recommendations for the management of systemic sclerosis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 322.	2.7	37
33	Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS). <i>Joint Bone Spine</i> , 2021, 88, 105162.	1.6	12
34	Epidemiology, Mortality and Healthcare Resource Utilization Associated With Systemic Sclerosis-Associated Interstitial Lung Disease in France. <i>Frontiers in Medicine</i> , 2021, 8, 699532.	2.6	5
35	Impact of Three Different Algorithms for the Screening of SSc-PAH and Comparison with the Decisions of a Multidisciplinary Team. <i>Diagnostics</i> , 2021, 11, 1738.	2.6	7
36	Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases. <i>European Journal of Internal Medicine</i> , 2021, 91, 45-52.	2.2	10

#	ARTICLE	IF	CITATIONS
37	Observance du traitement par hydroxychloroquine dans le lupus systémique: résultats contrastés et faible corrélation entre les outils d'évaluation. Revue Du Rhumatisme (Edition Francaise), 2021, 88, 369-376.	0.0	0
38	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases, 2021, 80, 930-942.	0.9	496
39	Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. Annals of the Rheumatic Diseases, 2021, 80, 329-338.	0.9	61
40	Passages in culture and stimulation conditions influence protein expression of primary fibroblasts. Proteomics, 2021, , 2100116.	2.2	0
41	Presentation and Real-World Management of Giant Cell Arteritis (Artemis Study). Frontiers in Medicine, 2021, 8, 732934.	2.6	10
42	Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study. Lancet Rheumatology, The, 2021, 3, e844-e854.	3.9	9
43	Practical management of patients on hydroxychloroquine. Joint Bone Spine, 2021, 88, 105316.	1.6	8
44	Concomitant fibromyalgia in primary Sjögren's syndrome in the French ASSESS cohort: comparison of the ACR 1990 and ACR 2016 criteria, FIRST questionnaire and physician's opinion. Clinical and Experimental Rheumatology, 2021, 39, 140-145.	0.8	5
45	Assessment of T-cell polarization on the basis of surface marker expression: Diagnosis and potential therapeutic implications in lymphocytic variant hypereosinophilic syndrome. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1110-1114.e2.	3.8	7
46	Characteristics and management of giant cell arteritis in France: a study based on national health insurance claims data. Rheumatology, 2020, 59, 120-128.	1.9	17
47	Systemic lupus erythematosus in Native sub-Saharan Africans: A systematic review and meta-analysis. Journal of Autoimmunity, 2020, 106, 102348.	6.5	35
48	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. Autoimmunity Reviews, 2020, 19, 102458.	5.8	231
49	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. Rheumatology, 2020, 59, 2016-2023.	1.9	14
50	Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibody-associated Vasculitis-related Bronchiectasis: Data from 61 Patients. Journal of Rheumatology, 2020, 47, 1522-1531.	2.0	10
51	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. Autoimmunity Reviews, 2020, 19, 102452.	5.8	43
52	Survival Improved in Patients Aged ≥ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. Chest, 2020, 157, 945-954.	0.8	13
53	Epidemiological data on systemic lupus erythematosus in native sub-Saharan Africans. Data in Brief, 2020, 28, 104909.	1.0	2
54	Exploring patient education unmet needs for rare and complex connective tissue and musculoskeletal diseases: A survey of health care providers' and patients' expectations in Europe. Chronic Illness, 2020, , 174239532096861.	1.5	5

#	ARTICLE	IF	CITATIONS
55	Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Annals of Internal Medicine</i> , 2020, 173, 179-187.	3.9	116
56	Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective study. <i>Autoimmunity Reviews</i> , 2020, 19, 102634.	5.8	14
57	Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. <i>Arthritis Research and Therapy</i> , 2020, 22, 257.	3.5	20
58	Obstetrical outcome and treatments in seronegative primary APS: data from European retrospective study. <i>RMD Open</i> , 2020, 6, e001340.	3.8	23
59	Clinical practice guidelines adherence, knowledge and awareness in rare and complex connective tissue diseases across Europe: results from the first ERN ReCONNET survey. <i>RMD Open</i> , 2020, 6, e001344.	3.8	6
60	Adherence to hydroxychloroquine in patients with systemic lupus: Contrasting results and weak correlation between assessment tools. <i>Joint Bone Spine</i> , 2020, 87, 603-610.	1.6	8
61	Rituximab and Cyclophosphamide in Antisynthetase Syndrome-related Interstitial Lung Disease: An Observational Retrospective Study. <i>Journal of Rheumatology</i> , 2020, 47, 1678-1686.	2.0	18
62	Outcomes of pregnancy and associated factors in sub-Saharan African women with systemic lupus erythematosus: a scoping review. <i>Lupus Science and Medicine</i> , 2020, 7, e000400.	2.7	4
63	Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2020, 22, 30.	3.5	20
64	Thrombocytopenia in primary antiphospholipid syndrome, a marker of high-risk patients?. <i>European Journal of Internal Medicine</i> , 2020, 74, 106-107.	2.2	12
65	Evolution of high-resolution CT-scan in systemic sclerosis-associated interstitial lung disease: Description and prognosis factors. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1406-1413.	3.4	11
66	Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1123-1125.	0.9	11
67	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 618-625.	0.9	71
68	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. <i>Journal of Psychosomatic Research</i> , 2020, 135, 110132.	2.6	21
69	Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. <i>Rheumatology</i> , 2020, 59, 3807-3816.	1.9	24
70	French recommendations for the management of systemic necrotizing vasculitides (polyarteritis) <i>TJ ETQq0 0 0 rgBT, Overlock 10 Tf 50 1</i>	2.7	39
71	Low hormone levels during an attack of systemic capillary leak syndrome normalizing after treatment. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.7	0
72	Consideration of coping strategies for patients suffering from systemic lupus erythematosus: reflection for a personalised practice of patient education. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 705-712.	0.8	2

#	ARTICLE	IF	CITATIONS
73	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <sc>SLE</sc>: Assessment by Drug Levels and Self-Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2019, 106, 374-382.	4.7	30
74	Imaging in Systemic Sclerosis: Make â€œUSâ€•Great Again? Comment on the Article by Santiago et al. Arthritis Care and Research, 2019, 71, 694-695.	3.4	2
75	Overall survival and mortality risk factors in Takayasu's arteritis: A multicenter study of 318 patients. Journal of Autoimmunity, 2019, 96, 35-39.	6.5	61
76	Campylobacter infection in adult patients with primary antibody deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1038-1041.e4.	3.8	7
77	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000786.	3.8	28
78	Positive Impact of Expert Reference Center Validation on Performance of Next-Generation Sequencing for Genetic Diagnosis of Autoinflammatory Diseases. Journal of Clinical Medicine, 2019, 8, 1729.	2.4	9
79	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatology, The, 2019, 1, e85-e94.	3.9	76
80	Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. Rheumatology, 2019, 58, 1565-1573.	1.9	28
81	The IgG2 Isotype of Anti-Transcription Intermediary Factor 1 ³ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis. Arthritis and Rheumatology, 2019, 71, 1360-1370.	5.6	33
82	Comment on: Is early-onset primary Sjögren's syndrome a worse prognosis form of the disease? Reply. Rheumatology, 2019, 58, 1312-1313.	1.9	2
83	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	5.6	75
84	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Annals of the Rheumatic Diseases, 2019, 78, 979-987.	0.9	142
85	IgG4-related diseases: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000787.	3.8	21
86	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000784.	3.8	19
87	Mixed connective tissue disease: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000783.	3.8	30
88	Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000782.	3.8	91
89	FRI0325â€¦IDENTIFYING SYSTEMIC SCLEROSIS PATIENTS AT RISK OF PROGRESSIVE LUNG FIBROSIS â€œ A EUSTAR DATABASE ANALYSIS. , 2019, , .		0
90	OP0239â€¦PROGRESSIVE LUNG FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN THE EUSTAR DATABASE. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
91	FRI0283â€¦PRESENTATION AND MANAGEMENT OF GIANT CELL ARTERITIS IN A REAL-WORLD SETTING (ARTEMIS) Tj ETQq1 1 0.784314		
92	The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder. <i>Lancet Rheumatology</i> , The, 2019, 1, e257-e264.	3.9	17
93	Is early-onset primary Sjögren's syndrome a worse prognosis form of the disease?. <i>Rheumatology</i> , 2019, 58, 1163-1167.	1.9	39
94	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	5.6	41
95	Systemic lupus erythematosus: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000793.	3.8	66
96	Remission of Refractory Systemic-Onset Juvenile Idiopathic Arthritis After Treatment With Siltuximab. <i>Journal of Clinical Rheumatology</i> , 2019, 25, e40-e42.	0.9	3
97	Patient acceptable symptom state and minimal clinically important difference for patient-reported outcomes in systemic sclerosis: A secondary analysis of a randomized controlled trial comparing personalized physical therapy to usual care. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 694-700.	3.4	18
98	Reply to Gilchrist et al. and to Musher. <i>Clinical Infectious Diseases</i> , 2018, 66, 637-638.	5.8	1
99	Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2017-212608.	0.9	181
100	Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. <i>Autoimmunity Reviews</i> , 2018, 17, 582-587.	5.8	74
101	S100A12 and S100A8/9 proteins are biomarkers of articular disease activity in Blau syndrome. <i>Rheumatology</i> , 2018, 57, 1299-1304.	1.9	12
102	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1646-1652.	3.4	8
103	Altered B lymphocyte homeostasis and functions in systemic sclerosis. <i>Autoimmunity Reviews</i> , 2018, 17, 244-255.	5.8	58
104	Validation of the Social Appearance Anxiety Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1557-1562.	3.4	17
105	Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review. <i>Journal of Rheumatology</i> , 2018, 45, 425-429.	2.0	23
106	Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. <i>American Journal of Hematology</i> , 2018, 93, 424-429.	4.1	56
107	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.9	50
108	Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating â€œnot applicableâ€ responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. <i>BMJ Open</i> , 2018, 8, e018641.	1.9	4

#	ARTICLE	IF	CITATIONS
109	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	1.9	53
110	Disease severity of proliferative lupus nephritis in Maghrebians. <i>Lupus</i> , 2018, 27, 1387-1392.	1.6	2
111	Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study. <i>Lupus</i> , 2018, 27, 357-364.	1.6	14
112	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. <i>Chest</i> , 2018, 153, 143-151.	0.8	68
113	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1074-1082.	4.7	48
114	Blau Syndrome—Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series. <i>American Journal of Ophthalmology</i> , 2018, 187, 158-166.	3.3	62
115	Prevalence and Clinical Associations of Antiphospholipid Antibodies in Systemic Sclerosis: New Data From a French Cross-Sectional Study, Systematic Review, and Meta-Analysis. <i>Frontiers in Immunology</i> , 2018, 9, 2457.	4.8	17
116	Sjögren's syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000789.	3.8	34
117	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000785.	3.8	38
118	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018, 52, 1800678.	6.7	60
119	Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. <i>JAMA Neurology</i> , 2018, 75, 1528.	9.0	301
120	Soluble HLA-G Expression Inversely Correlates With Fetal Microchimerism Levels in Peripheral Blood From Women With Scleroderma. <i>Frontiers in Immunology</i> , 2018, 9, 1685.	4.8	6
121	Whole-Body Distribution and Clinical Association of Telangiectases in Systemic Sclerosis. <i>JAMA Dermatology</i> , 2018, 154, 796.	4.1	14
122	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. <i>Arthritis and Rheumatology</i> , 2018, 70, 1829-1834.	5.6	15
123	Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients. <i>Journal of Clinical Immunology</i> , 2018, 38, 503-512.	3.8	9
124	Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study. <i>BioMed Research International</i> , 2018, 2018, 1-10.	1.9	3
125	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. <i>PLoS ONE</i> , 2018, 13, e0197112.	2.5	47
126	Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 127.	2.7	19

#	ARTICLE	IF	CITATIONS
127	In silico validation of the Autoinflammatory Disease Damage Index. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1599-1605.	0.9	27
128	Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome. <i>Lupus</i> , 2018, 27, 1679-1686.	1.6	25
129	Mortality in systemic necrotizing vasculitides: A retrospective analysis of the French Vasculitis Study Group registry. <i>Autoimmunity Reviews</i> , 2018, 17, 653-659.	5.8	40
130	Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study). <i>Respiratory Research</i> , 2018, 19, 84.	3.6	7
131	Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology. <i>Current Research in Translational Medicine</i> , 2018, 66, 83-86.	1.8	9
132	Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients. <i>Clinical Immunology</i> , 2018, 197, 54-59.	3.2	51
133	A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren's syndrome. <i>Rheumatology</i> , 2017, 56, kew376.	1.9	38
134	Role of B cells in the pathogenesis of systemic sclerosis. <i>Revue De Medecine Interne</i> , 2017, 38, 113-124.	1.0	37
135	Controlling the digital ulcerative disease in systemic sclerosis is associated with improved hand function. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 759-766.	3.4	8
136	Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. <i>Journal of Rheumatology</i> , 2017, 44, 639-647.	2.0	93
137	Development of the autoinflammatory disease damage index (ADDI). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 821-830.	0.9	68
138	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.9	132
139	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. <i>Journal of Medical Genetics</i> , 2017, 54, 288-296.	3.2	262
140	Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1388-1393.e8.	2.9	222
141	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1042-1050.	0.9	132
142	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.9	107
143	Diagnosis of primary antibody and complement deficiencies in young adults after a first invasive bacterial infection. <i>Clinical Microbiology and Infection</i> , 2017, 23, 576.e1-576.e5.	6.0	25
144	Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature. <i>Autoimmunity Reviews</i> , 2017, 16, 377-384.	5.8	49

#	ARTICLE	IF	CITATIONS
145	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32
146	Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis. <i>European Respiratory Journal</i> , 2017, 49, 1700178.	6.7	9
147	The Clinical Picture of Severe Systemic Capillary-Leak Syndrome Episodes Requiring ICU Admission. <i>Critical Care Medicine</i> , 2017, 45, 1216-1223.	0.9	56
148	Intravenous Immunoglobulins Improve Survival in Monoclonal Gammopathy-Associated Systemic Capillary-Leak Syndrome. <i>American Journal of Medicine</i> , 2017, 130, 1219.e19-1219.e27.	1.5	53
149	Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. <i>Journal of Autoimmunity</i> , 2017, 80, 10-27.	6.5	114
150	Specific Polysaccharide Antibody Deficiency Revealed by Severe Bacterial Infections in Adulthood: A Report on 11 Cases. <i>Clinical Infectious Diseases</i> , 2017, 65, 328-331.	5.8	15
151	Transethnic meta-analysis identifies <i>GSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1150-1158.	0.9	77
152	Familial and syndromic lupus share the same phenotype as other early-onset forms of lupus. <i>Joint Bone Spine</i> , 2017, 84, 589-593.	1.6	7
153	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.9	794
154	Pulmonary hypertension in systemic sclerosis: different phenotypes. <i>European Respiratory Review</i> , 2017, 26, 170056.	7.1	97
155	Cogan syndrome: Characteristics, outcome and treatment in a French nationwide retrospective study and literature review. <i>Autoimmunity Reviews</i> , 2017, 16, 1219-1223.	5.8	47
156	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.9	410
157	An international SURvey on non-invasive techniques to assess the microcirculation in patients with Raynaud's phenomenon (SUNSHINE survey). <i>Rheumatology International</i> , 2017, 37, 1879-1890.	3.0	33
158	Prevalence of primary immunodeficiencies in France is underestimated. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1731-1733.	2.9	32
159	Ophthalmic manifestations in IgG4-related disease. <i>Medicine (United States)</i> , 2017, 96, e6205.	1.0	65
160	Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2209-2221.	5.6	17
161	Incidence, risk factors, and mortality of neonatal and late-onset dilated cardiomyopathy associated with cardiac neonatal lupus. <i>International Journal of Cardiology</i> , 2017, 248, 263-269.	1.7	37
162	Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2370-2379.	5.6	49

#	ARTICLE	IF	CITATIONS
163	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. <i>European Heart Journal</i> , 2017, 38, 2649-2662.	2.2	163
164	Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis. <i>Circulation</i> , 2017, 136, 1114-1122.	1.6	161
165	Patients'™ views and needs about systemic sclerosis and its management: a qualitative interview study. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 230.	1.9	42
166	A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 54.	2.7	32
167	Postrehabilitation Functional Improvements in Patients With Inflammatory Myopathies: The Results of a Randomized Controlled Trial. <i>Archives of Physical Medicine and Rehabilitation</i> , 2017, 98, 227-234.	0.9	31
168	High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance. <i>International Journal of Neuroscience</i> , 2017, 127, 516-523.	1.6	14
169	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-blind, Placebo-controlled Trials. <i>Arthritis and Rheumatology</i> , 2017, 69, 362-375.	5.6	189
170	Real-world Experience and Impact of Canakinumab in Cryopyrin-associated Periodic Syndrome: Results From a French Observational Study. <i>Arthritis Care and Research</i> , 2017, 69, 903-911.	3.4	14
171	Personalized Physical Therapy Versus Usual Care for Patients With Systemic Sclerosis: A Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2017, 69, 1050-1059.	3.4	52
172	Severe Health-related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-reported Outcomes: Data From a Large Therapeutic Trial. <i>Arthritis Care and Research</i> , 2017, 69, 528-535.	3.4	65
173	Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. <i>Lupus</i> , 2017, 26, 163-169.	1.6	53
174	Systemic capillary leak syndrome and autoimmune diseases: A case series. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 509-512.	3.4	16
175	Two-year follow-up after endobronchial coil treatment in emphysema: results from the REVOLENS study. <i>European Respiratory Journal</i> , 2017, 50, 1701740.	6.7	12
176	B Cell Homeostasis and Functional Properties Are Altered in an Hypochlorous Acid-Induced Murine Model of Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2017, 8, 53.	4.8	14
177	Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. <i>PLoS ONE</i> , 2017, 12, e0181692.	2.5	68
178	Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. <i>PLoS ONE</i> , 2017, 12, e0183844.	2.5	174
179	Factors associated with the 6-minute walk distance in patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2017, 19, 279.	3.5	22
180	Pulmonary hypertension subtypes associated with hereditary haemorrhagic telangiectasia: Haemodynamic profiles and survival probability. <i>PLoS ONE</i> , 2017, 12, e0184227.	2.5	21

#	ARTICLE	IF	CITATIONS
181	Patient phenotypes in fibromyalgia comorbid with systemic sclerosis or rheumatoid arthritis: influence of diagnostic and screening tests. Screening with the FIRST questionnaire, diagnosis with the ACR 1990 and revised ACR 2010 criteria. Clinical and Experimental Rheumatology, 2017, 35 Suppl 105, 35-42.	0.8	12
182	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Annals of the Rheumatic Diseases, 2016, 75, 103-109.	0.9	93
183	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Annals of the Rheumatic Diseases, 2016, 75, 163-169.	0.9	82
184	Does the route of immunoglobulin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages". Orphanet Journal of Rare Diseases, 2016, 11, 83.	2.7	28
185	High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary Sjögren's Syndrome: Data from the TEARS Randomized Trial. PLoS ONE, 2016, 11, e0162787.	2.5	43
186	Anti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and Lupus. PLoS ONE, 2016, 11, e0160283.	2.5	1
187	Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2016, 68, 977-985.	5.6	146
188	Observational Study of a French and Belgian Multicenter Cohort of 23 Patients Diagnosed in Adulthood With Mevalonate Kinase Deficiency. Medicine (United States), 2016, 95, e3027.	1.0	24
189	Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. Arthritis and Rheumatology, 2016, 68, 1522-1530.	5.6	131
190	Pulmonary arterial hypertension in idiopathic inflammatory myopathies. Medicine (United States), 2016, 95, e4911.	1.0	40
191	Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. Annals of the Rheumatic Diseases, 2016, 75, 1743-1748.	0.9	68
192	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Annals of the Rheumatic Diseases, 2016, 75, 1009-1015.	0.9	112
193	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Annals of the Rheumatic Diseases, 2016, 75, 1945-1950.	0.9	57
194	Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort. RMD Open, 2016, 2, e000179.	3.8	88
195	Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease. Lupus, 2016, 25, 1440-1447.	1.6	19
196	Subcutaneous Immunoglobulin Therapy Prevents Systemic Capillary Leak Syndrome Attack. American Journal of Medicine, 2016, 129, e77-e78.	1.5	7
197	Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. Lupus, 2016, 25, 1420-1430.	1.6	49
198	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. Arthritis and Rheumatology, 2016, 68, 2527-2539.	5.6	122

#	ARTICLE	IF	CITATIONS
199	Exclusion of Patients with a Severe T-Cell Defect Improves the Definition of Common Variable Immunodeficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 1147-1157.	3.8	45
200	N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. <i>International Journal of Cardiology</i> , 2016, 223, 385-389.	1.7	16
201	18F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis. <i>Medicine (United States)</i> , 2016, 95, e3851.	1.0	80
202	Long-term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2016, 68, 690-701.	5.6	101
203	B-cell and T-cell quantification in minor salivary glands in primary Sjögren's syndrome: development and validation of a pixel-based digital procedure. <i>Arthritis Research and Therapy</i> , 2016, 18, 21.	3.5	20
204	Special considerations in pregnant systemic sclerosis patients. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1161-1173.	3.0	19
205	Efficacy of Anti-TNF α in Severe and Refractory Neuro-Behcet Disease. <i>Medicine (United States)</i> , 2016, 95, e3550.	1.0	43
206	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 382-389.	0.9	225
207	Digital ulcers predict a worse disease course in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 681-686.	0.9	111
208	Coexistence of rheumatoid arthritis and TEMPI syndrome: New insight in microangiogenic-related diseases. <i>Joint Bone Spine</i> , 2016, 83, 587-588.	1.6	10
209	Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 175.	7.4	171
210	Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases. <i>Autoimmunity Reviews</i> , 2016, 15, 281-286.	5.8	49
211	Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome. <i>Journal of Autoimmunity</i> , 2016, 67, 102-110.	6.5	68
212	Understanding remission in real-world lupus patients across five European countries. <i>Lupus</i> , 2016, 25, 505-512.	1.6	17
213	Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies. <i>American Journal of Pathology</i> , 2016, 186, 691-700.	3.8	78
214	Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). <i>Current Rheumatology Reports</i> , 2016, 18, 10.	4.7	38
215	Effect of Iterative Reconstruction on the Detection of Systemic Sclerosis-related Interstitial Lung Disease: Clinical Experience in 55 Patients. <i>Radiology</i> , 2016, 279, 297-305.	7.3	36
216	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1285-1292.	0.9	56

#	ARTICLE	IF	CITATIONS
217	Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 780-783.	0.9	40
218	A prospective study of the 6-minute walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1457-1465.	0.9	16
219	Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide. <i>PLoS ONE</i> , 2016, 11, e0151696.	2.5	13
220	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. <i>PLoS ONE</i> , 2016, 11, e0163894.	2.5	158
221	A candidate gene study identifies a haplotype of CD2 as novel susceptibility factor for systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 43-48.	0.8	1
222	Myocarditis in Patients With Antisynthetase Syndrome. <i>Medicine (United States)</i> , 2015, 94, e798.	1.0	47
223	Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. <i>Annals of Neurology</i> , 2015, 78, 901-916.	5.3	143
224	Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2015, 67, 2176-2184.	5.6	118
225	Distinctive Patterns of Transthyretin Amyloid in Salivary Tissue. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1035-1044.	3.7	18
226	Identification of NF- κ B and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 71.	3.5	41
227	Musculoskeletal Symptoms in Patients With Cryopyrin-Associated Periodic Syndromes: A Large Database Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 3027-3036.	5.6	24
228	Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?. <i>PLoS ONE</i> , 2015, 10, e0133907.	2.5	19
229	Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti-Synthetase Auto-Antibodies: An Open-Label, Phase II Trial. <i>PLoS ONE</i> , 2015, 10, e0133702.	2.5	84
230	EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015, 1, e000022-e000022.	3.8	229
231	In Antisynthetase Syndrome, ACPA Are Associated With Severe and Erosive Arthritis. <i>Medicine (United States)</i> , 2015, 94, e798.	1.0	47
232	Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. <i>Rheumatology</i> , 2015, 54, 1262-1269.	1.9	25
233	Selexipag for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2015, 373, 2522-2533.	27.0	790
234	Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agency for Health and Safety (ANRS) (ANRS 20 Mortality 2010 survey). <i>HIV Medicine</i> , 2015, 16, 230-239.	2.2	71

#	ARTICLE	IF	CITATIONS
235	Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients. <i>Rheumatology</i> , 2015, 54, 927-932.	1.9	37
236	Efficacy and safety of a new oral saliva equivalent in the management of xerostomia: a national, multicenter, randomized study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015, 119, 301-309.	0.4	16
237	AA amyloidosis treated with tocilizumab: case series and updated literature review. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2015, 22, 84-92.	3.0	37
238	CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. <i>Haematologica</i> , 2015, 100, 1086-95.	3.5	37
239	Reliability of histopathological salivary gland biopsy assessment in Sjogren's syndrome: a multicentre cohort study. <i>Rheumatology</i> , 2015, 54, 1056-1064.	1.9	47
240	Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. <i>Rheumatology</i> , 2015, 54, 1699-1708.	1.9	49
241	Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. <i>Journal of Autoimmunity</i> , 2015, 62, 67-74.	6.5	178
242	Impairment of quality of life in patients with antiphospholipid syndrome. <i>Lupus</i> , 2015, 24, 1161-1168.	1.6	25
243	ANCA-associated vasculitis in patients with primary Sjögren's syndrome: Detailed analysis of 7 new cases and systematic literature review. <i>Autoimmunity Reviews</i> , 2015, 14, 742-750.	5.8	52
244	Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 19.	2.7	117
245	Chronic histiocytic intervillositis: Outcome, associated diseases and treatment in a multicenter prospective study. <i>Autoimmunity</i> , 2015, 48, 40-45.	2.6	62
246	A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR- γ) gene and systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 128.	3.5	24
247	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1124-1131.	0.9	96
248	DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. <i>Lupus</i> , 2015, 24, 648-649.	1.6	26
249	Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30 Suppl 1, i104-12.	0.7	45
250	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015, 102, 19-24.	2.5	13
251	Takayasu Arteritis and Pregnancy. <i>Arthritis and Rheumatology</i> , 2015, 67, 3262-3269.	5.6	65
252	Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. <i>Autoimmunity Reviews</i> , 2015, 14, 1154-1160.	5.8	121

#	ARTICLE	IF	CITATIONS
253	Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2006-2015.	0.9	231
254	Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes. <i>Rheumatology</i> , 2015, 54, 1008-1016.	1.9	141
255	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 859-866.	0.9	193
256	Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1011-1018.	0.9	610
257	The Clinical Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data From a French Nationwide Study of Fifty-seven Patients. <i>Arthritis and Rheumatology</i> , 2015, 67, 527-534.	5.6	136
258	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. <i>Thorax</i> , 2014, 69, 436-444.	5.6	100
259	Ischemic Digital Ulcers Affect Hand Disability and Pain in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2014, 41, 1317-1323.	2.0	58
260	Gastrointestinal mucosal abnormalities using videocapsule endoscopy in systemic sclerosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 189-199.	3.7	42
261	Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up. <i>Lupus Science and Medicine</i> , 2014, 1, e000027.	2.7	54
262	Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89 patients treated since specific approval. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 398-402.	1.1	12
263	Kikuchi-Fujimoto Disease. <i>Medicine (United States)</i> , 2014, 93, 372-382.	1.0	160
264	Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. <i>Medicine (United States)</i> , 2014, 93, 340-349.	1.0	122
265	Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysis. <i>Rheumatology</i> , 2014, 53, 639-643.	1.9	8
266	Reconciling Healthcare Professional and Patient Perspectives in the Development of Disease Activity and Response Criteria in Connective Tissue Disease-related Interstitial Lung Diseases. <i>Journal of Rheumatology</i> , 2014, 41, 792-798.	2.0	43
267	Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab. <i>Clinical Rheumatology</i> , 2014, 33, 799-805.	2.2	35
268	Clinical picture and treatment of 2212 patients with common variable immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 116-126.e11.	2.9	512
269	Immunological profiles determine neurological involvement in Sjögren's syndrome. <i>European Journal of Internal Medicine</i> , 2014, 25, 177-181.	2.2	48
270	Prevalence of Anti-RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2014, 66, 407-417.	5.6	76

#	ARTICLE	IF	CITATIONS
271	Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: A french multicenter study. Autoimmunity Reviews, 2014, 13, 1035-1041.	5.8	94
272	Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 2087-2093.	0.9	168
273	Systemic sclerosis and prevalence of monoclonal immunoglobulin. Autoimmunity Reviews, 2014, 13, 1189-1194.	5.8	9
274	Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. Presse Medicale, 2014, 43, e345-e363.	1.9	42
275	Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Annals of the Rheumatic Diseases, 2014, 73, 2074-2081.	0.9	204
276	Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmunity Reviews, 2014, 13, 974-980.	5.8	34
277	Biologic targeted therapies in pediatric rheumatology. Joint Bone Spine, 2014, 81, 2-48.	1.6	5
278	Exposure to ACE inhibitors prior to the onset of scleroderma renal crisisâ€”Results from the International Scleroderma Renal Crisis Survey. Seminars in Arthritis and Rheumatism, 2014, 43, 666-672.	3.4	115
279	Association study of CRP gene in systemic sclerosis in European Caucasian population. Rheumatology International, 2014, 34, 389-392.	3.0	2
280	Treatment of Primary Sjögren Syndrome With Rituximab. Annals of Internal Medicine, 2014, 160, 233-242.	3.9	325
281	Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood, 2014, 124, 1119-1126.	1.4	208
282	The Spectrum of Renal Involvement in Patients With Inflammatory Myopathies. Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.0	35
283	Elevated Plasma Fibrinogen in Clinically Asymptomatic Unicentric Castleman's Disease: A Case Report. Journal of Clinical and Experimental Hematopathology: JCEH, 2014, 54, 85-88.	0.8	4
284	Granulomatous Disease in CVID: Retrospective Analysis of Clinical Characteristics and Treatment Efficacy in a Cohort of 59 Patients. Journal of Clinical Immunology, 2013, 33, 84-95.	3.8	125
285	Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 330-340.	27.0	1,120
286	Hydroxychloroquine-Induced Pigmentation in Patients With Systemic Lupus Erythematosus. JAMA Dermatology, 2013, 149, 935.	4.1	91
287	Survival and Prognostic Factors in Systemic Sclerosisâ€”Associated Pulmonary Hypertension: A Systematic Review and Metaâ€Analysis. Arthritis and Rheumatism, 2013, 65, 2412-2423.	6.7	205
288	Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Medicale, 2013, 42, 1317-1330.	1.9	62

#	ARTICLE	IF	CITATIONS
289	Recommendations for Screening and Detection of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatism</i> , 2013, 65, 3194-3201.	6.7	175
290	Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome. <i>European Journal of Internal Medicine</i> , 2013, 24, 474-479.	2.2	66
291	Multidimensional analysis of clinical symptoms in patients with Fabry's disease. <i>International Journal of Clinical Practice</i> , 2013, 67, 120-127.	1.7	15
292	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. <i>Arthritis and Rheumatism</i> , 2013, 65, 270-281.	6.7	670
293	Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon β mimetic. <i>Arthritis and Rheumatism</i> , 2013, 65, 447-456.	6.7	155
294	Recurrent limb and facial oedema with R92Q mutation: A non-febrile late-onset tumour necrosis factor receptor-associated periodic syndrome (TRAPS)? <i>Presse Medicale</i> , 2013, 42, 905-906.	1.9	0
295	Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database. <i>Microvascular Research</i> , 2013, 89, 122-128.	2.5	101
296	Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. <i>Clinical and Experimental Immunology</i> , 2013, 171, 186-194.	2.6	55
297	European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: A Complete Picture of Primary Sjögren's Syndrome Patients. <i>Arthritis Care and Research</i> , 2013, 65, 1358-1364.	3.4	71
298	Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. <i>European Respiratory Journal</i> , 2013, 42, 1271-1282.	6.7	108
299	Study of Anti-Müllerian Hormone and Its Relation to the Subsequent Probability of Pregnancy in 112 Patients With Systemic Lupus Erythematosus, Exposed or Not to Cyclophosphamide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3785-3792.	3.6	51
300	Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1786-1792.	0.9	160
301	Systemic Vasculitis During the Course of Systemic Sclerosis. <i>Medicine (United States)</i> , 2013, 92, 1-9.	1.0	54
302	Brief Report: A Regulatory Variant in <i>CCR6</i> Is Associated With Susceptibility to Antitopoisomerase-Positive Systemic Sclerosis. <i>Arthritis and Rheumatism</i> , 2013, 65, 3202-3208.	6.7	26
303	Long-term outcome in idiopathic granulomatous mastitis: a western multicentre study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 433-441.	0.5	49
304	Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1940-1946.	0.9	128
305	Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1026-1031.	0.9	193
306	Interstitial Lung Disease in Anti-CCP1 Patients With Antisynthetase Syndrome. <i>Arthritis Care and Research</i> , 2013, 65, 800-808.	3.4	114

#	ARTICLE	IF	CITATIONS
307	Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjögren's syndrome. <i>Blood</i> , 2013, 122, 4068-4076.	1.4	103
308	Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome. <i>Arthritis Research and Therapy</i> , 2013, 15, R149.	3.5	50
309	Effect of In Vitro and In Vivo Anakinra on Cytokines Production in Schnitzler Syndrome. <i>PLoS ONE</i> , 2013, 8, e59327.	2.5	31
310	Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren's Syndrome. Data at Enrollment in the Prospective ASSESS Cohort. <i>PLoS ONE</i> , 2013, 8, e59868.	2.5	147
311	Relevance of Partitioning DLCO to Detect Pulmonary Hypertension in Systemic Sclerosis. <i>PLoS ONE</i> , 2013, 8, e78001.	2.5	15
312	Osteolytic Lesion with Thick Sclerotic Walls and Demyelinating Polyneuropathy. <i>Journal of Rheumatology</i> , 2012, 39, 2175-2176.	2.0	1
313	Myocardial involvement in systemic capillary leak syndrome: first demonstration by pathologic findings. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2012, 1, 248-252.	1.0	17
314	Lupus Anticoagulant-Hypoprothrombinemia Syndrome. <i>Medicine (United States)</i> , 2012, 91, 251-260.	1.0	85
315	Prevalence, characteristics and prognostic significance of anemia in daily practice. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 345-354.	0.5	17
316	Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1355-1360.	0.9	275
317	Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. <i>Rheumatology</i> , 2012, 51, 460-467.	1.9	147
318	Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1034-1041.	0.9	33
319	Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 718-721.	0.9	96
320	Comparing HLA Shared Epitopes in French Caucasian Patients with Scleroderma. <i>PLoS ONE</i> , 2012, 7, e36870.	2.5	19
321	Malignant Retroperitoneal Fibrosis. <i>Medicine (United States)</i> , 2012, 91, 242-250.	1.0	26
322	Independent Replication and Metaanalysis of Association Studies Establish TNFSF4 as a Susceptibility Gene Preferentially Associated with the Subset of Anticentromere-positive Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 997-1003.	2.0	35
323	The Relapsing Polychondritis Disease Activity Index: Development of a disease activity score for relapsing polychondritis. <i>Autoimmunity Reviews</i> , 2012, 12, 204-209.	5.8	71
324	Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. <i>Autoimmunity Reviews</i> , 2012, 12, 210-217.	5.8	233

#	ARTICLE	IF	CITATIONS
325	TGF β 2 receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1900-1903.	0.9	18
326	Pulmonary perfusion scintigraphy: A tool to detect the presence of pulmonary artery involvement in Takayasu's arteritis. <i>Presse Medicale</i> , 2012, 41, e37-e42.	1.9	19
327	Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. <i>British Journal of Dermatology</i> , 2012, 167, 1138-1144.	1.5	91
328	Clinical Assessment of Pulmonary Hypertension. , 2012, , 429-435.		0
329	Treatment of Systemic Sclerosis Complications: What to Use When First-Line Treatment Failsâ€”A Consensus of Systemic Sclerosis Experts. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 42-55.	3.4	107
330	Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group. <i>Arthritis Research and Therapy</i> , 2012, 14, R37.	3.5	41
331	Could the Cochin risk prediction score be applied in daily practice to predict pulmonary hypertension in systemic sclerosis? Comment on the article by Meune et al. <i>Arthritis and Rheumatism</i> , 2012, 64, 2051-2052.	6.7	2
332	Brief Report: Candidate gene study in systemic sclerosis identifies a rare and functional variant of the <i>TNFAIP3</i> locus as a risk factor for polyautoimmunity. <i>Arthritis and Rheumatism</i> , 2012, 64, 2746-2752.	6.7	63
333	Abatacept therapy and safety management. <i>Joint Bone Spine</i> , 2012, 79, 3-84.	1.6	49
334	Fabry disease â€”The New Great Imposterâ€™™: results of the French Observatoire in Internal Medicine Departments (FIMeD). <i>Clinical Genetics</i> , 2012, 81, 571-577.	2.0	59
335	Parental Consanguinity is Associated with a Severe Phenotype in Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2012, 32, 98-105.	3.8	27
336	Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patients. <i>Lupus</i> , 2011, 20, 861-865.	1.6	30
337	Expert Agreement on EULAR/EUSTAR Recommendations for the Management of Systemic Sclerosis: Table 1.. <i>Journal of Rheumatology</i> , 2011, 38, 1326-1328.	2.0	54
338	<i>NLRP1</i> influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 668-674.	0.9	83
339	Defects in the CD19 complex predispose to glomerulonephritis, as well as IgG1 subclass deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 538-541.e5.	2.9	31
340	Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 382-389.e1.	2.9	128
341	Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 364-368.	1.3	31
342	EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 968-972.	0.9	383

#	ARTICLE	IF	CITATIONS
343	Autoimmunity in common variable immunodeficiency: Correlation with lymphocyte phenotype in the French DEFI study. <i>Journal of Autoimmunity</i> , 2011, 36, 25-32.	6.5	117
344	Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 632-643.	0.6	95
345	Pulmonary manifestations of Sjögren's syndrome. <i>Presse Medicale</i> , 2011, 40, e71-e86.	1.9	61
346	Infectious Complications in Polymyositis and Dermatomyositis: A Series of 279 Patients. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 48-60.	3.4	107
347	TNF alpha antagonist therapy and safety monitoring. <i>Joint Bone Spine</i> , 2011, 78, 15-185.	1.6	65
348	Active Immunological Profile Is Associated with Systemic Sjögren's Syndrome. <i>Journal of Clinical Immunology</i> , 2011, 31, 840-847.	3.8	76
349	Vertebral fractures in Gaucher disease type I: data from the French "Observatoire" on Gaucher disease (FROG). <i>Osteoporosis International</i> , 2011, 22, 1255-1261.	3.1	16
350	Diagnosis and Classification of Systemic Sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2011, 40, 78-83.	6.5	142
351	Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. <i>Arthritis Research and Therapy</i> , 2011, 13, R202.	3.5	106
352	Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers. <i>Arthritis Care and Research</i> , 2011, 63, 277-285.	3.4	94
353	Recommendations for the care of oral involvement in patients with systemic sclerosis. <i>Arthritis Care and Research</i> , 2011, 63, 1126-1133.	3.4	68
354	Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren's syndrome: A national multicentric retrospective study. <i>Arthritis Care and Research</i> , 2011, 63, 1339-1344.	3.4	61
355	Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. <i>Arthritis and Rheumatism</i> , 2011, 63, 295-304.	6.7	163
356	Association of the CD226 Ser ³⁰⁷ variant with systemic sclerosis: Evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. <i>Arthritis and Rheumatism</i> , 2011, 63, 1097-1105.	6.7	49
357	C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: Results from a large french cohort and meta-analysis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2091-2096.	6.7	45
358	Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survival. <i>Arthritis and Rheumatism</i> , 2011, 63, 3522-3530.	6.7	291
359	Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: Association with the functional IRAK1 196Phe/532Ser haplotype. <i>Arthritis and Rheumatism</i> , 2011, 63, 3979-3987.	6.7	56
360	Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies. <i>European Respiratory Journal</i> , 2011, 37, 714-717.	6.7	46

#	ARTICLE	IF	CITATIONS
361	Mevalonate Kinase Deficiency: A Survey of 50 Patients. <i>Pediatrics</i> , 2011, 128, e152-e159.	2.1	195
362	The oxidation induced by antityeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis. <i>European Respiratory Journal</i> , 2011, 37, 1503-1513.	6.7	42
363	Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening. <i>European Respiratory Review</i> , 2011, 20, 270-276.	7.1	26
364	<i>Pneumocystis jirovecii</i> colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. <i>Rheumatology</i> , 2011, 50, 569-577.	1.9	39
365	Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 495-499.	0.9	146
366	An exceptional minute tumour incidentally found in a renal biopsy. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1436-1438.	0.7	0
367	Association Study of <i>ITGAM</i> , <i>ITGAX</i> , and <i>CD58</i> Autoimmune Risk Loci in Systemic Sclerosis: Results from 2 Large European Caucasian Cohorts. <i>Journal of Rheumatology</i> , 2011, 38, 1033-1038.	2.0	22
368	Clinical Characteristics and Survival in Systemic Sclerosis-Related Pulmonary Hypertension Associated With Interstitial Lung Disease. <i>Chest</i> , 2011, 140, 1016-1024.	0.8	89
369	Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2095-2102.	0.9	182
370	Genome-Wide Scan Identifies <i>TNIP1</i> , <i>PSORS1C1</i> , and <i>RHOB</i> as Novel Risk Loci for Systemic Sclerosis. <i>PLoS Genetics</i> , 2011, 7, e1002091.	3.5	205
371	Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study. <i>Rheumatology</i> , 2011, 50, 1440-1444.	1.9	62
372	Independent replication establishes the <i>CD247</i> gene as a genetic systemic sclerosis susceptibility factor. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1695-1696.	0.9	46
373	Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. <i>Rheumatology</i> , 2011, 50, 2283-2289.	1.9	56
374	Anti-synthetase syndrome positive for anti-isoleucyl-tRNA synthetase antibodies: an unusual case overlapping with systemic sclerosis and Sjogren's syndrome. <i>Rheumatology</i> , 2011, 50, 1175-1176.	1.9	16
375	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. <i>Chest</i> , 2010, 138, 462-463.	0.8	1
376	Graft-versus-host disease-related polymyositis. <i>Clinical Rheumatology</i> , 2010, 29, 431-433.	2.2	15
377	B-Cell and T-Cell Phenotypes in CVID Patients Correlate with the Clinical Phenotype of the Disease. <i>Journal of Clinical Immunology</i> , 2010, 30, 746-755.	3.8	150
378	The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG). <i>Journal of Inherited Metabolic Disease</i> , 2010, 33, 331-338.	3.6	63

#	ARTICLE	IF	CITATIONS
379	Tocilizumab: Therapy and safety management. <i>Joint Bone Spine</i> , 2010, 77, S3-S100.	1.6	52
380	Immunological profile in primary Sjögren syndrome. <i>Autoimmunity Reviews</i> , 2010, 9, 595-599.	5.8	103
381	The French national registry of primary immunodeficiency diseases. <i>Clinical Immunology</i> , 2010, 135, 264-272.	3.2	137
382	Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index. <i>Arthritis Care and Research</i> , 2010, 62, 551-558.	3.4	66
383	Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: A series of 73 patients. <i>Arthritis Care and Research</i> , 2010, 62, 1748-1755.	3.4	115
384	Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. <i>Arthritis and Rheumatism</i> , 2010, 62, 616-626.	6.7	483
385	Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. <i>Arthritis and Rheumatism</i> , 2010, 62, 2458-2466.	6.7	352
386	Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. <i>Arthritis and Rheumatism</i> , 2010, 62, 2625-2632.	6.7	266
387	Association of a <i>KCNK5</i> gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. <i>Arthritis and Rheumatism</i> , 2010, 62, 3093-3100.	6.7	49
388	Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody. <i>British Journal of Dermatology</i> , 2010, 162, 337-344.	1.5	78
389	STAT4 is a confirmed genetic risk factor for Sjögren's syndrome and could be involved in type 1 interferon pathway signaling. <i>Genes and Immunity</i> , 2010, 11, 432-438.	4.1	71
390	Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. <i>Rheumatology</i> , 2010, 49, 940-944.	1.9	53
391	Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management. <i>European Respiratory Review</i> , 2010, 19, 314-320.	7.1	33
392	Association Between a CTGF Gene Polymorphism and Systemic Sclerosis in a French Population. <i>Journal of Rheumatology</i> , 2010, 37, 351-358.	2.0	27
393	Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2010, 36, 549-555.	6.7	582
394	Endothelial dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodies. <i>Rheumatology</i> , 2010, 49, 1049-1055.	1.9	51
395	Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database. <i>Journal of Rheumatology</i> , 2010, 37, 1488-1501.	2.0	161
396	Association of Metalloproteinase Gene Polymorphisms with Systemic Sclerosis in the European Caucasian Population. <i>Journal of Rheumatology</i> , 2010, 37, 599-602.	2.0	10

#	ARTICLE	IF	CITATIONS
397	Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. <i>Rheumatology</i> , 2010, 49, 972-976.	1.9	75
398	Association of the <i>TNFAIP3</i> rs5029939 variant with systemic sclerosis in the European Caucasian population. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1958-1964.	0.9	120
399	Phenotype-Haplotype Correlation of <i>IRF5</i> in Systemic Sclerosis: Role of 2 Haplotypes in Disease Severity. <i>Journal of Rheumatology</i> , 2010, 37, 987-992.	2.0	54
400	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1809-1815.	0.9	1,017
401	Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 218-221.	0.9	214
402	EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1103-1109.	0.9	734
403	Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPiB 2008 study. <i>Journal of Hepatology</i> , 2010, 53, 1006-1012.	3.7	46
404	Comparison of the Farr radioimmunoassay, 3 commercial enzyme immunoassays and <i>Crithidia luciliae</i> immunofluorescence test for diagnosis and activity assessment of systemic lupus erythematosus. <i>Clinica Chimica Acta</i> , 2010, 411, 959-964.	1.1	30
405	Prognosis Assessment of Cardiac Involvement in Systemic AL Amyloidosis by Magnetic Resonance Imaging. <i>American Journal of Medicine</i> , 2010, 123, 864-868.	1.5	59
406	Association Study of Serotonin Transporter Gene (SLC6A4) in Systemic Sclerosis in European Caucasian Populations. <i>Journal of Rheumatology</i> , 2010, 37, 1164-1167.	2.0	10
407	Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era. <i>Circulation</i> , 2010, 122, 156-163.	1.6	1,264
408	Myopathies related to systemic sclerosis: a case-control study of associated clinical and immunological features. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 498-505.	1.1	64
409	Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients. <i>Rheumatology</i> , 2010, 49, 1164-1172.	1.9	93
410	Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. <i>Arthritis and Rheumatism</i> , 2009, 61, 108-118.	6.7	98
411	Diluted Russell viper-venom time improves identification of antiphospholipid syndrome in a lupus anticoagulant-positive patient population. <i>Thrombosis and Haemostasis</i> , 2009, 101, 577-581.	3.4	9
412	Clinical Features of Scleroderma Patients With or Without Prior or Current Ischemic Digital Ulcers: Post-Hoc Analysis of a Nationwide Multicenter Cohort (ItinAIR-Sclerodermie). <i>Journal of Rheumatology</i> , 2009, 36, 1470-1476.	2.0	86
413	Clinical and Morphologic Spectrum of Renal Involvement in Patients With Mixed Cryoglobulinemia Without Evidence of Hepatitis C Virus Infection. <i>Medicine (United States)</i> , 2009, 88, 341-348.	1.0	79
414	Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1878-1884.	0.9	227

#	ARTICLE	IF	CITATIONS
415	Male microchimerism and HLA compatibility in French women with scleroderma: a different profile in limited and diffuse subset. <i>Rheumatology</i> , 2009, 48, 363-366.	1.9	32
416	Aortic aneurysm in MAGIC syndrome successfully managed with combined anti-TNF- α and stent grafting. <i>Rheumatology</i> , 2009, 48, 1169-1170.	1.9	15
417	Subluxing arthropathy: an unusual manifestation of the antisynthetase syndrome. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 152-153.	0.9	23
418	Abatacept therapy and safety management. <i>Joint Bone Spine</i> , 2009, 76, S3-S55.	1.6	38
419	Association between the <i>IRF5</i> rs2004640 functional polymorphism and systemic sclerosis: A new perspective for pulmonary fibrosis. <i>Arthritis and Rheumatism</i> , 2009, 60, 225-233.	6.7	180
420	The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. <i>Arthritis and Rheumatism</i> , 2009, 60, 1831-1839.	6.7	179
421	The CCGGG insertion/deletion polymorphism of the <i>IRF5</i> promoter is a strong risk factor for primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2009, 60, 1991-1997.	6.7	104
422	<i>STAT4</i> is a genetic risk factor for systemic sclerosis having additive effects with <i>IRF5</i> on disease susceptibility and related pulmonary fibrosis. <i>Arthritis and Rheumatism</i> , 2009, 60, 2472-2479.	6.7	139
423	<i>BANK1</i> is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with <i>IRF5</i> and <i>STAT4</i> . <i>Arthritis and Rheumatism</i> , 2009, 60, 3447-3454.	6.7	105
424	Kidney transplantation in patients with Fabry disease. <i>Transplant International</i> , 2009, 22, 475-481.	1.6	35
425	Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalit� 2005 survey, ANRS) <i>TJ ETQ</i> 11 0.784314 r gBT /O verlock 10	1.4	10
426	A descriptive and prognostic study of systemic sclerosis-associated myopathies. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1474-1477.	0.9	87
427	Th1 and Th17 balance in inflammatory myopathies: Interaction with dendritic cells and possible link with response to high-dose immunoglobulins. <i>Cytokine</i> , 2009, 46, 297-301.	3.2	54
428	Gaucher disease and monoclonal gammopathy: A report of 17 cases and impact of therapy. <i>Blood Cells, Molecules, and Diseases</i> , 2009, 43, 138-139.	1.4	25
429	Vaccination in adults with auto-immune disease and/or drug related immune deficiency: Results of the GEVACCIM Delphi survey. <i>Vaccine</i> , 2009, 27, 1523-1529.	3.8	18
430	Maladie de Takayasu: caract�ristiques cliniques, prise en charge diagnostique, traitement et pronostic. <i>Medecine Nucleaire</i> , 2009, 33, 512-517.	0.2	4
431	Effective immune restoration after immunosuppressant discontinuation in a lupus patient presenting progressive multifocal leukoencephalopathy. <i>Journal of the Neurological Sciences</i> , 2009, 287, 246-249.	0.6	14
432	Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome. <i>New England Journal of Medicine</i> , 2009, 360, 2416-2425.	27.0	754

#	ARTICLE	IF	CITATIONS
433	Angiotensin-Converting Enzyme Gene Does Not Contribute to Genetic Susceptibility to Systemic Sclerosis in European Caucasians. <i>Journal of Rheumatology</i> , 2009, 36, 337-340.	2.0	15
434	Tadalafil Therapy for Pulmonary Arterial Hypertension. <i>Circulation</i> , 2009, 119, 2894-2903.	1.6	956
435	Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1428-1432.	0.9	262
436	Late-Onset Combined Immune Deficiency: A Subset of Common Variable Immunodeficiency with Severe T Cell Defect. <i>Clinical Infectious Diseases</i> , 2009, 49, 1329-1338.	5.8	192
437	Association of hypoxia-inducible factor 1A (<i>HIF1A</i>) gene polymorphisms with systemic sclerosis in a French European Caucasian population. <i>Scandinavian Journal of Rheumatology</i> , 2009, 38, 291-294.	1.1	29
438	Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. <i>Lancet</i> , The, 2009, 374, 1986-1996.	13.7	246
439	Beneficial effect of intravenous immunoglobulins on systemic capillary leak syndrome in patients with monoclonal gammopathy. <i>Critical Care Medicine</i> , 2009, 37, 795.	0.9	4
440	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. <i>Chest</i> , 2009, 136, 1211-1219.	0.8	117
441	Rituximab (MabThera) therapy and safety management. Clinical tool guide developed by the Rheumatic Diseases & Inflammation Group (Club Rhumatismes et Inflammation, CRI) of the French Society for Rheumatology (Société Française de Rhumatologie, SFR). <i>Joint Bone Spine</i> , 2008, 75, S2-S99.	1.6	29
442	Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. <i>Rheumatology</i> , 2008, 48, 304-308.	1.9	148
443	Infections in 252 Patients with Common Variable Immunodeficiency. <i>Clinical Infectious Diseases</i> , 2008, 46, 1547-1554.	5.8	394
444	High-dose intravenous immunoglobulins dramatically reverse systemic capillary leak syndrome. <i>Critical Care Medicine</i> , 2008, 36, 2184-2187.	0.9	124
445	Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. <i>Journal of Rheumatology</i> , 2008, 35, 1064-72.	2.0	99
446	Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 351-357.	0.9	261
447	Pulmonary Arterial Hypertension: A Rare Complication of Primary Sjogren Syndrome. <i>Medicine (United Tj ETQq1</i> 0.784314 169 /Ov	1.0	169
448	Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach. <i>Arthritis and Rheumatism</i> , 2007, 56, 3420-3432.	6.7	54
449	Association of an <i>IRF5</i> gene functional polymorphism with Sjogren's syndrome. <i>Arthritis and Rheumatism</i> , 2007, 56, 3989-3994.	6.7	173
450	Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. <i>Journal of Rheumatology</i> , 2007, 34, 1005-11.	2.0	84

#	ARTICLE	IF	CITATIONS
451	Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. <i>Journal of Rheumatology</i> , 2007, 34, 2423-30.	2.0	148
452	Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. <i>Arthritis and Rheumatism</i> , 2006, 54, 1697-1700.	6.7	100
453	The complexity of managing systemic sclerosis: screening and diagnosis. <i>Rheumatology</i> , 2006, 48, iii8-iii13.	1.9	32
454	Pulmonary Arterial Hypertension in France. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1023-1030.	5.6	1,736
455	High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. <i>Journal of Rheumatology</i> , 2006, 33, 1789-801.	2.0	126
456	Opportunistic infections in polymyositis and dermatomyositis. <i>Arthritis and Rheumatism</i> , 2005, 53, 155-165.	6.7	154
457	Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. <i>Arthritis and Rheumatism</i> , 2005, 52, 3792-3800.	6.7	656
458	MR Imaging Findings in Hands in Early Rheumatoid Arthritis: Comparison with Those in Systemic Lupus Erythematosus and Primary Sjögren Syndrome. <i>Radiology</i> , 2005, 236, 593-600.	7.3	93
459	Neurologic Manifestations in Primary Sjögren Syndrome. <i>Medicine (United States)</i> , 2004, 83, 280-291.	1.0	536
460	Inaugural raynaud's phenomenon is associated with a multisystemic involvement during follow-up in primary sjögren's syndrome—A report of 162 patients. <i>International Journal of Angiology</i> , 2004, 13, 71-74.	0.6	4
461	Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. <i>Clinical Rheumatology</i> , 2004, 23, 516-522.	2.2	39
462	Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS). <i>Arthritis and Rheumatism</i> , 2004, 50, 1270-1276.	6.7	368
463	Diagnostic tools for amyloidosis. <i>Joint Bone Spine</i> , 2002, 69, 538-545.	1.6	63
464	Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. <i>Journal of Rheumatology</i> , 2002, 29, 75-83.	2.0	114
465	Influence of Age on Characteristics of Polymyositis and Dermatomyositis in Adults. <i>Medicine (United States)</i> , 2001, 80, 1078-1083.	1.0	159
466	Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. a prospective clinical and immunohistologic study in 59 patients. <i>Arthritis and Rheumatism</i> , 1993, 36, 691-697.	6.7	96
467	Late Skin Fibrosis in Systemic Sclerosis: A Study from the EUSTAR Cohort. <i>Rheumatology</i> , 2000, 39, 1055-1060.	1.9	3